Summary of Key Points
iFlytek Medical's 2026 Half-Year Report Surpassed Market Expectations: Revenue Increased by 49.4%, Gross Profit Increased by 53.5%, Losses Narrowed by 20%, and Stock Price Rose by Over 16%. Securities Firms Are Generally Optimistic. The Critical Change is the Shift in Business Model from “One-Time Project Sales” to “Sustainable Operating Revenue.” Policy Support, Hospitals' Urgent Needs, and Technological Breakthroughs Are Together Driving the Commercial Closure Loop of Large Medical Models, with a Profit Turnpoint Approaching, Potentially Reshaping the Valuation of the Medical AI Sector.
I. Outstanding Half-Year Report: Quality of Growth Is More Important Than Speed
iFlytek Medical's revenue for the first half of the year was 446 million yuan (up 49.4%), and its gross profit was 236 million yuan (up 53.5%). The faster growth in gross profit indicates that it is not relying on low-price strategies or a large number of projects, but rather an increase in the proportion of high-gross-profit AI software/services. Losses have decreased from 74 million yuan last year to 59.3 million yuan (a 20% reduction), meaning the company is burning money more slowly and is getting closer to profitability.
For example, in the past, selling a hospital project might result in a large profit, but the costs were also high. Now, by providing AI diagnostic and treatment assistance services on a per-use basis (such as charging per document generated for medical records), the costs are lower, and revenue is generated continuously, which is why the gross profit is increasing more rapidly.
II. Major Shift in Business Model: From “One-Time Sales” to “Sustainable Revenue”
The past challenge in the AI healthcare industry was that the technology was impressive, but hospitals were reluctant to pay for ongoing services. The reason was that the project-based model (custom development for each hospital) was costly, and revenue was only received once, similar to a one-time deal.
Now, iFlytek Medical has made the following changes:
- AI Diagnostic and Treatment Assistant: Charges are based on the number of medical records adopted (for example, 1 yuan per record generated). The more hospitals use the service, the more they pay, providing sustainable revenue.
- AI Health Assistant: Revenue comes from renewing contracts with existing customers (for example, annual renewals for imaging cloud services), with an increase in average transaction value, rather than expanding new customer bases. This “operating model” is similar to a subscription service, providing stable cash flow and low marginal costs, which is a key breakthrough in the business model.
III. Policy Support + Hospitals' Urgent Needs: AI Healthcare Becoming a “Must-Have”
Why are hospitals now willing to invest in AI healthcare?
1. Policy Drivers: The government is promoting new healthcare infrastructure, requiring AI to optimize resource allocation (such as distributing high-quality resources to grassroots hospitals).
2. Hospitals' Own Pressures: Changes in payment systems like DRG/DIP (where excess expenses are not compensated) and stricter doctor evaluations mean that AI can help reduce the burden on doctors (e.g., automatically generating medical records, identifying unreasonable prescriptions), improving efficiency, and saving money.
For instance, iFlytek's Intelligent Medical Assistant has been adopted by 77,000 grassroots hospitals, helping doctors prescribe the right medications and write standardized medical records. These services are essential for grassroots hospitals, not just additional perks.
IV. Three Main Business Segments: Health Assistant Becomes the Growth Driver
iFlytek focuses on three main segments:
- AI Diagnostic and Treatment Assistant: The core business, accounting for 45% of revenue, covering grassroots hospitals in 31 provinces with a market share of over 80%, assisting doctors in clinical decision-making.
- AI Health Assistant: The fastest-growing segment, accounting for 41% of revenue, with a focus on imaging cloud services (e.g., saving 2 billion yuan in medical insurance costs in Anhui Province) and expanding into other medical technology services such as laboratory and pathology. The company has also won a 5-year project in Ningxia.
- AI Digital Foundation: Gross profit increased by 22.7 percentage points, with a shift in resources towards sustainable revenue, optimizing the profit structure.
The high growth of the Health Assistant segment indicates that the business model has successfully transitioned from a hospital-centric (G-side) approach to a patient/consumer-centric (C-side) one, expanding the market potential.
V. Profit Turnpoint Approaching: The Capital Market Is Voting With Its Dollars
Why is it expected that profitability will increase soon?
- Seasonal Peak in the Second Half of the Year: The healthcare IT industry sees more project confirmations in the second half of the year, leading to higher revenue.
- Accelerated ARR (Annual Recurring Revenue) Transformation: The proportion of annual recurring revenue is increasing, indicating better revenue quality.
- Positive Views from Securities Firms: China Merchants Bank International has raised its target price to HK$99.58 (current price is around HK$67, with room for a 50% increase), and Guosheng Securities predicts profitability to start in 2026 (revenue of 16 million yuan).
This is a landmark event for the entire medical AI sector, proving that large medical models are not only technically advanced but also profitable, which will prompt investors to re-evaluate the industry's value.
Conclusion
iFlytek Medical's half-year report marks a significant milestone as large medical models move from being a showcase of technology to a viable and profitable business model. With policy support, hospitals' urgent needs, and an upgraded business model, the company is getting closer to profitability, giving the entire industry a boost. AI healthcare is no longer just a concept; it is a practical and profitable business opportunity.